Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.
1. Overall survival was significantly greater in the fruquintinib group versus placebo. 2. The majority of adverse events were mild-to-moderate and were slightly more common among patients receiving fruquintinib. Evidence Rating Level: 1 (Excellent) Study Rundown: Colorectal cancer is the third-most prevalent cancer in the world and the second leading cause of death worldwide. Patients